ArticleThe Journal of clinical investigation2025
Identification of potent biparatopic antibodies targeting FGFR2 fusion-driven cholangiocarcinoma.
Saireudee Chaturantabut et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it